Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding double-blind trial of grass pollen immunotherapy for allergic rhinitis/rhinoconjunctivitis
2014-005471-88Phase 2Active
- Sponsor
- INMUNOTEK, S.L.
- Start
- Sep 2015
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MG56 grass pollen immunotherapy in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and grass pollen allergy (8 arms), sponsored by INMUNOTEK, S.L. Primary endpoint: Change in NPT threshold concentration. Started Sep 2015; status: active.
02
Drugs
MG56 grass pollen immunotherapy
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)grass pollen allergy
Beyond the preview
Go deeper on 2014-005471-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005471-88.